Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

C. C. Hofmeister, B. Jansak, N. Denlinger, E. H. Kraut, D. M. Benson, Sherif Farag

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As2O3) with DVd (Doxil™, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25 mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd.

Original languageEnglish
Pages (from-to)1295-1298
Number of pages4
JournalLeukemia Research
Volume32
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Phase II Clinical Trials
Vincristine
Multiple Myeloma
Dexamethasone
Hypocalcemia
Hyponatremia
Hyperglycemia
Appointments and Schedules
liposomal doxorubicin
arsenic trioxide

Keywords

  • Arsenic
  • Doxorubicin
  • Multiple myeloma
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. / Hofmeister, C. C.; Jansak, B.; Denlinger, N.; Kraut, E. H.; Benson, D. M.; Farag, Sherif.

In: Leukemia Research, Vol. 32, No. 8, 08.2008, p. 1295-1298.

Research output: Contribution to journalArticle

Hofmeister, C. C. ; Jansak, B. ; Denlinger, N. ; Kraut, E. H. ; Benson, D. M. ; Farag, Sherif. / Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. In: Leukemia Research. 2008 ; Vol. 32, No. 8. pp. 1295-1298.
@article{c7f65566ac484aa180609870a714f01e,
title = "Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma",
abstract = "In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As2O3) with DVd (Doxil™, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25 mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd.",
keywords = "Arsenic, Doxorubicin, Multiple myeloma, Vincristine",
author = "Hofmeister, {C. C.} and B. Jansak and N. Denlinger and Kraut, {E. H.} and Benson, {D. M.} and Sherif Farag",
year = "2008",
month = "8",
doi = "10.1016/j.leukres.2007.10.020",
language = "English",
volume = "32",
pages = "1295--1298",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

AU - Hofmeister, C. C.

AU - Jansak, B.

AU - Denlinger, N.

AU - Kraut, E. H.

AU - Benson, D. M.

AU - Farag, Sherif

PY - 2008/8

Y1 - 2008/8

N2 - In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As2O3) with DVd (Doxil™, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25 mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd.

AB - In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As2O3) with DVd (Doxil™, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25 mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd.

KW - Arsenic

KW - Doxorubicin

KW - Multiple myeloma

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=43049117226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049117226&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.10.020

DO - 10.1016/j.leukres.2007.10.020

M3 - Article

C2 - 18082257

AN - SCOPUS:43049117226

VL - 32

SP - 1295

EP - 1298

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -